Published in J Clin Oncol on January 01, 2006
Diffuse glioma growth: a guerilla war. Acta Neuropathol (2007) 2.11
Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci (Landmark Ed) (2010) 1.87
Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med (2007) 1.57
Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res (2013) 1.51
Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol (2008) 1.47
Implication of tumor microenvironment in chemoresistance: tumor-associated stromal cells protect tumor cells from cell death. Int J Mol Sci (2012) 1.32
The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. Expert Opin Biol Ther (2009) 1.29
Immunotherapy of malignant brain tumors. Immunol Rev (2008) 1.20
Clinical radioimmunotherapy--the role of radiobiology. Nat Rev Clin Oncol (2011) 1.10
Cancer radioimmunotherapy. Immunotherapy (2011) 1.10
Radioimmunotherapy of human tumours. Nat Rev Cancer (2015) 1.07
Use of antibodies and immunoconjugates for the therapy of more accessible cancers. Adv Drug Deliv Rev (2008) 1.00
A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro Oncol (2008) 0.99
Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors. Future Oncol (2013) 0.97
Radioimmunotherapy of solid tumors: searching for the right target. Curr Drug Deliv (2011) 0.96
Cancer Imaging and Therapy with Bispecific Antibody Pretargeting. Update Cancer Ther (2007) 0.90
Glycoproteomic analysis of two mouse mammary cell lines during transforming growth factor (TGF)-beta induced epithelial to mesenchymal transition. Proteome Sci (2009) 0.88
Effective radiovirotherapy for malignant gliomas by using oncolytic measles virus strains encoding the sodium iodide symporter (MV-NIS). Hum Gene Ther (2012) 0.88
Interstitial infusion of glioma-targeted recombinant immunotoxin 8H9scFv-PE38. Mol Cancer Ther (2010) 0.85
Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer. Expert Opin Drug Deliv (2014) 0.85
Which radionuclides will nuclear oncology need tomorrow? Eur J Nucl Med Mol Imaging (2006) 0.85
Tenascin-C: Exploitation and collateral damage in cancer management. Cell Adh Migr (2015) 0.85
Current available therapies and future directions in the treatment of malignant gliomas. Biologics (2009) 0.83
Molecular targeted α-particle therapy for oncologic applications. AJR Am J Roentgenol (2014) 0.81
Antibody-based immunotherapy for malignant glioma. Semin Oncol (2014) 0.80
Quantitative analysis of three-dimensional human mammary epithelial tissue architecture reveals a role for tenascin-C in regulating c-met function. Am J Pathol (2009) 0.80
A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG). Cancers (Basel) (2011) 0.79
Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization. Adv Drug Deliv Rev (2016) 0.79
Evaluation of biodistribution and antitumor effects of (188)Re-rhk5 in a mouse model of lung cancer. Oncol Lett (2011) 0.77
Cancer microenvironment and cancer vaccine. Cancer Microenviron (2012) 0.77
Glioblastoma multiforme: emerging treatments and stratification markers beyond new drugs. Br J Radiol (2015) 0.76
Radiation therapy for prevention of heterotopic ossification about the elbow. Strahlenther Onkol (2009) 0.76
The Similarities and Differences between Intracranial and Spinal Ependymomas : A Review from a Genetic Research Perspective. J Korean Neurosurg Soc (2016) 0.75
Passive immunotherapeutic strategies for the treatment of malignant gliomas. Neurosurg Clin N Am (2012) 0.75
Expression of HMP/AN2, a melanoma associated antigen, in murine cerebral gliomas: potential for radioimmunotargeting. J Neurooncol (2009) 0.75
Radiolabelled monoclonal antibodies in the treatment of metastatic cancer. Curr Oncol (2007) 0.75
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature (2006) 27.91
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol (2007) 12.62
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res (2007) 9.21
The genetic landscape of the childhood cancer medulloblastoma. Science (2010) 8.34
Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA (2011) 6.92
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88
Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res (2006) 6.77
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol (2010) 6.30
Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell (2009) 5.81
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer (2007) 5.28
Novel mutations target distinct subgroups of medulloblastoma. Nature (2012) 4.82
Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med (2008) 4.71
Altered telomeres in tumors with ATRX and DAXX mutations. Science (2011) 4.60
Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer (2007) 4.54
Video-assisted thoracic surgery lobectomy: report of CALGB 39802--a prospective, multi-institution feasibility study. J Clin Oncol (2007) 4.42
Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev (2002) 4.30
Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res (2004) 4.26
Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. N Engl J Med (2005) 4.26
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat Med (2012) 4.11
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget (2012) 3.88
Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol (2008) 3.84
Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol (2003) 3.83
Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell (2010) 3.82
Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. Ann Thorac Surg (2006) 3.76
Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc Natl Acad Sci U S A (2011) 3.66
Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol (2012) 3.66
Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell (2004) 3.63
The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle (2009) 3.55
Clinical applications of PET in oncology. Radiology (2004) 3.44
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol (2009) 3.39
Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell (2013) 3.32
Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res (2006) 3.28
Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study. Cancer (2002) 3.23
Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med (2006) 3.15
Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma. Cancer Cell (2009) 3.11
Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial. Lancet (2010) 3.07
Notch promotes radioresistance of glioma stem cells. Stem Cells (2010) 3.07
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res (2006) 3.02
Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro Oncol (2007) 2.99
Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res (2008) 2.97
Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J Clin Oncol (2008) 2.96
Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics. Radiology (2002) 2.95
Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opin Investig Drugs (2009) 2.90
The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet (2013) 2.89
Newborn screening for Krabbe disease: the New York State model. Pediatr Neurol (2009) 2.88
Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncol (2013) 2.82
A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol (2010) 2.79
The incidence and functional consequences of RT-associated cardiac perfusion defects. Int J Radiat Oncol Biol Phys (2005) 2.70
Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol (2006) 2.69
Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res (2005) 2.63